Immunex' Leukine and Amgen's Neupogen cleared for peripheral blood progenitor cell mobilization.
Executive Summary
IMMUNEX LEUKINE AND AMGEN NEUPOGEN CLEARED FOR PBPC MOBILIZATION by FDA Dec. 22 and Dec. 28, respectively. Mobilization of peripheral blood progenitor cells and post-PBPC transplantation use is the fifth approved indication for Leukine (sargramostim, GM-CSF) and the fourth for Neupogen (filgrastim, G-CSF).